Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida
October 4, 2024
Claudio Mateus Gnoatto, Keyla Liana Bezerra Machado, Rian Ricardo Henrique da Silva et al.
Introdução: O Transtorno Depressivo Maior (TDM) é altamente prevalente e incapacitante, ocupando um alto ônus globalmente. No Brasil, afeta 15,5% da população. A fisiopatologia da depressão envolve teorias, incluindo a monoaminérgica e a dos receptores monoaminérgicos, embora nenhuma seja conclusiva. Tratamentos farmacológicos baseiam-se na teoria monoaminérgica, apesar de suas limitações. Além...
British Journal of Pharmacology
October 2, 2024
Ryan H. Gumpper, David E Nichols
9 citations
This brief review highlights some of the structure-activity relationships of classic serotonergic psychedelics. In particular, we discuss structural features of three chemotypes: phenethylamines, ergolines and certain tryptamines, which possess psychedelic activity in humans. Where they are known, we point out the underlying molecular mechanisms utilized by each of the three chemotypes of...
Behavioural Pharmacology
October 1, 2024
David R Maguire
2 citations
There has been substantial and growing interest in the therapeutic utility of drugs acting at serotonin 2A subtype (5-HT 2A ) receptors, increasing the need for characterization of potential beneficial and adverse effects of such compounds. Although numerous studies have evaluated the possible rewarding and reinforcing effects of 5-HT 2A receptor agonists, there have been relatively few studies...
Journal of the Chinese Medical Association : JCMA
October 1, 2024
Mu-Hong Chen, Tung-Ping Su, Ju-Wei Hsu et al.
14 citations
The concurrent rise in the prevalence of autism and youth suicide has drawn public health and professional attention. The renaissance of psychedelics in psychiatry occurred in the early 21st century and may suggest a hope for the therapeutic effect of psychedelics in autism and suicide. The psychedelics' molecular entities are the compounds that modulate the serotoninergic and glutamatergic...
Electromagnetic biology and medicine
October 1, 2024
Mary O Vu, B Michael Butters, Clinton E. Canal et al.
1 citation
Results from clinical trials show that serotonergic psychedelics have efficacy in treating psychiatric disorders, where currently approved pharmacotherapies are inadequate. Developing psychedelic medicines, however, comes with unique challenges, such as tempering heightened anxiety associated with the psychedelic experience. We conceived a new strategy to potentially mitigate psychedelic...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
October 1, 2024
Manoj K. Doss, Pablo Mallaroni, Natasha L. Mason et al.
7 citations
As research on psychedelics (hallucinogenic serotonin receptor 2A agonists) progresses, it is important to delineate the reliability of supposedly unique effects across this drug class. One such effect is how psychedelics impair the formation (i.e., encoding) of hippocampal-dependent recollections (retrieval of specific details) while potentially enhancing the encoding of cortical-dependent...
Translational Psychiatry
September 30, 2024
Aaron Klaiber, Yasmin Schmid, Anna M Becker et al.
27 citations
Classic psychedelics have regained interest in research and therapy. Despite the long tradition of the human use of mescaline, modern data on its dose-dependent acute effects and pharmacokinetics are lacking. Additionally, its mechanism of action has not been investigated in humans. We used a randomized, double-blind, placebo-controlled, crossover design in 16 healthy subjects (8 women) who...
Middle East Research Journal of Biological Sciences
September 28, 2024
Carlos Henrique Marchiori, Marco Vinícios de Oliveira Santana, Klebert de Paula Malheiros
Psilocybin and psilocin do not cause addiction or dependence, as they do not interact with the dopaminergic reward system. New pharmacological treatment strategies for substance abuse disorders have targeted craving, which is characterized, in a simplified way, by an intense desire to use the substance. Psilocybin is an indole alkaloid of the hallucinogenic tryptamine group whose molecular...
Communications in Humanities Research
September 27, 2024
Yichen Liu
As the diagnosis rate of depression continues to rise, effective treatment options for this condition have become one of the most researched areas in the field. Earlier antidepressants were primarily developed based on mechanisms that involve regulating imbalanced neurotransmitters. For example, the widely known Selective Serotonin Reuptake Inhibitors (SSRIs) and various tricyclic...
Cambridge Quarterly of Healthcare Ethics
September 27, 2024
Daniel Villiger
10 citations
Classic serotonergic psychedelics are experiencing a clinical revival, which has also revived ethical debates about psychedelic-assisted therapy. A particular issue here is how to prepare and protect patients from the vulnerability that the psychedelic state creates. This paper first examines how this vulnerability manifests itself, revealing that it results from an impairment of autonomy:...